Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis

Trial Profile

A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maralixibat (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CAMEO
  • Sponsors Lumena Pharmaceuticals; Mirum Pharmaceuticals; Shire
  • Most Recent Events

    • 18 May 2023 Results presented in the Mirum Pharmaceuticals Media Release.
    • 18 May 2023 According to a Mirum Pharmaceuticals media release, data from the study was published in Hepatology Communications.
    • 01 Oct 2019 According to a Mirum Pharmaceuticals media release, results from this study will be presented at The Liver Meeting 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top